(i.e., addition of sulfasalazine and hydroxychloroquine) for patients taking maximally tolerated doses of methotrexate who are not at target The panel vigorously debated whether to recommend addition of a bDMARD or tsDMARD versus sulfasalazine and hydroxychloroquine (triple therapy) for patients with an inadequate response to methotrexate monotherapy in view of very low-certainty evidence favoring bDMARDs or tsDMARDs, randomized controlled trials demonstrating equivalent long-term outcomes